Soaring sales of 'dangerous' do-it-yourself DNA test kits: Number of websites selling products doubles in two years
By Sean Poulter,
Daily Mail (UK)
| 01. 20. 2014
- 38 British websites now offer home testing kits - which can cost up to £300
- Paternity and genetic ancestry tests are the most popular
- Tests which claim to reveal vulnerability to diseases are also up
Sales of DNA tests for everything from the risk of developing life-threatening diseases to catching out cheating partners are booming.
The number of British websites offering home testing kits and services has doubled to 38 in just two years, research has revealed, with companies charging fees of up to £300.
DIY paternity and genetic ancestry tests are the biggest sellers, however sales of tests claiming to reveal a predisposition to certain diseases are up 14 per cent a year.
The revelation by Angelina Jolie that she had a double mastectomy because she had a greater genetic risk of developing breast cancer triggered a spike in tests.
Genetic tests also now exist for a host of serious inherited illnesses, such as Huntington’s disease or Parkinsons.
However, the advances open up potentially devastating consequences for people who get bad news about their risk of developing a fatal...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...